title: Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
abstract: The pharmacokinetics of R- and S-flecainide have been determined in five poor (PM) and five extensive (EM) metabolisers of sparteine/debrisoquine under conditions of uncontrolled urine flow and pH. The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h). The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1). The renal clearance, however, was comparable for both enantiomers in both EMs and PMs, and therefore the phenotypic differences in flecainide disposition observed must be due to differences in metabolic clearance. The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1). The partial clearance to the two major metabolites meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) was significantly lower in poor (62 ml.min-1) than extensive (267 ml.min-1) metabolisers. The impairment in flecainide metabolism in poor metabolisers of sparteine/debrisoquine has therefore been confirmed. Under conditions reflecting the clinical situation the difference in disposition between EMs and PMs would be considerable. However, it may be predicted that at standard doses concentrations greater than 1000 ng.ml-1 would not be attained in the PMs studied.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, FRG.
authors.forename: A S
authors.initials: AS
authors.lastname: Gross
authors.forename: G
authors.initials: G
authors.lastname: Mikus
authors.forename: C
authors.initials: C
authors.lastname: Fischer
authors.forename: M
authors.initials: M
authors.lastname: Eichelbaum
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D003640:Dealkylation; D003647:Debrisoquin / Q000378:metabolism; D005260:Female; D005424:Flecainide / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D011110:Polymorphism, Genetic; D011485:Protein Binding; D013034:Sparteine / Q000378:metabolism; D013237:Stereoisomerism; D014554:Urination
chemical_list: D013034:Sparteine; D005424:Flecainide; D003647:Debrisoquin